120
Participants
Start Date
April 26, 2023
Primary Completion Date
March 18, 2025
Study Completion Date
April 16, 2027
Setmelanotide
Solution for daily subcutaneous injection
Placebo
Placebo matched to setmelanotide for daily subcutaneous injection
Columbia University Irving Medical Center, New York
Children's Hospital of Philadelphia, Philadelphia
Universitaetsklinikum Hamburg-Eppendorf (UKE) - Ambulanzzentrum des UKE GmbH, Hamburg
University Children's Hospital, Klinikum Oldenburg, Oldenburg
UAN Pediatric Endocrinology, Birmingham
Vanderbilt University School of Medicine, Nashville
Ohio State Wexner Medical Center, Columbus
University of Iowa Stead Family Department of Pediatrics, Iowa City
Children's Minnesota, Saint Paul
Ann and Robert H. Lurie Children's Hospital, Chicago
Lynn Health Science Institute, Oklahoma City
Children's Hospital Colorado, Aurora
Medicover Neuroendokrinologie, München
Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin, Ulm
Rady Children's Hospital, San Diego
Seattle Children's Hospital, Research and Foundation - Center for Integrative Brain Research, Seattle
Icahn School of Medicine at Mount Sinai, New York
University of Florida, Gainesville
Boston Children's Hospital, Boston
Brigham and Women's Hospital, Boston
Hospital for Sick Children, Toronto
Nagoya City University Hospital, Nagoya
Nagano Children's Hospital, Azumino
Toranomon Hospital, Minato
Prinses Maxima Center for Pediatric Oncology, Utrecht
Birmingham Women and Children's Hospital NHS Trust, Birmingham
Hull University Teaching Hospital, Hull
UCL Great Ormond Street Institute of Child Health, London
Rhythm Pharmaceuticals, Inc.
INDUSTRY